Cowen set a $55.00 price objective on Adamas Pharmaceuticals (NASDAQ:ADMS) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities research analysts have also recently issued reports about the stock. Mizuho reissued a buy rating and issued a $48.00 price target (up from $26.00) on shares of Adamas Pharmaceuticals in a research report on Tuesday, September 19th. Needham & Company LLC reissued a buy rating and issued a $38.00 price target on shares of Adamas Pharmaceuticals in a research report on Sunday, September 17th. Noble Financial restated a buy rating and issued a $33.00 price objective on shares of Adamas Pharmaceuticals in a research note on Friday, September 29th. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Thursday, September 21st. Finally, ValuEngine upgraded shares of Adamas Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Adamas Pharmaceuticals currently has an average rating of Buy and an average price target of $42.00.

Shares of Adamas Pharmaceuticals (ADMS) opened at $32.58 on Wednesday. Adamas Pharmaceuticals has a 1 year low of $13.50 and a 1 year high of $38.22. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.03). During the same quarter in the previous year, the firm earned ($0.66) EPS. The firm’s revenue for the quarter was down 99.3% on a year-over-year basis. research analysts expect that Adamas Pharmaceuticals will post -3.84 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC acquired a new position in Adamas Pharmaceuticals during the second quarter worth about $109,000. SG Americas Securities LLC acquired a new position in Adamas Pharmaceuticals during the third quarter worth about $110,000. Quantbot Technologies LP acquired a new position in Adamas Pharmaceuticals during the third quarter worth about $119,000. Virtu KCG Holdings LLC acquired a new position in Adamas Pharmaceuticals during the second quarter worth about $184,000. Finally, Sei Investments Co. grew its position in Adamas Pharmaceuticals by 1,105.0% during the third quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock worth $185,000 after buying an additional 8,033 shares during the period. Institutional investors own 79.45% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/adamas-pharmaceuticals-adms-pt-set-at-55-00-by-cowen/1769075.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.